Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Inder Anand
Prof. Gerhard Hindricks,
By Inder Anand, (Minneapolis, United States of America)View Discussant reportRead the press releaseOpen the PresentationWatch the Webcast
List of Authors: Rajendra K. Premchand, Kamal Sharma, Sanjay Mittal, Rufino Monteiro, Imad Libbus, Lorenzo DiCarlo, Jeffrey L. Ardell, Thomas S. Rector, Badri Amurthur, Bruce H. KenKnight, Inder S. Anand
ObjectiveANTHEM-HF evaluated a novel autonomic regulation therapy (ART) via either left or right vagus nerve stimulation (VNS) in patients with heart failure (HF) and reduced ejection fraction (HFrEF).Methods and ResultsSixty subjects (NYHA class II-III, LVEF40%, LVEDD50 mm and <80 mm) receiving optimal pharmacological therapy were randomized at 10 sites. VNS systems were randomly implanted on the left (n=31) or right side (n=29). All patients were successfully implanted and 59 were titrated over 10 weeks to a well-tolerated chronic intermittent stimulation (10 Hz, 250 µs, 14 sec on, 66 s off). The current amplitude was titrated to prevent side effects and acute HR changes (average up-titrated output current was 2.0 ± 0.6 mA). One patient died 3 days after an embolic stroke that occurred during implant. Common device-related adverse events after VNS titration were transient mild dysphonia, cough, and oropharyngeal pain, similar for left- and right-sided VNS. After 6 months of ART, in the combined population, absolute LVEF improved by 4.5% [95% CI2.4 to 6.6], LVESV improved by -4.1 mL [-9.0 to 0.8], and LVESD improved by -1.7 mm [-2.8 to -0.7]. The adjusted left-right differences in LVEF, end-systolic volume (LVESV), and end-systolic diameter (LVESD) were 0.2% [-4.4 to 4.7], 3.7 mL [-7.0 to 14.4], and 1.3 mm [-0.9 to 3.6], respectively. Heart rate variability improved by 17 ms [6.5 to 28] with minimal left-right difference. Six-minute walk distance improved an average of 56 m [37 to 75]; however, improvement was greater for right-sided ART (77 m [49 to 105]). NYHA class improved in 77% of patients (baseline to 6 months). ConclusionsChronic, low-amplitude ART via left- or right-sided VNS is feasible and well-tolerated in HFrEF patients. Safety assessment do not raise concerns, efficacy measures are encouraging and warrant further study.
By Gerhard Hindricks, FESC (Leipzig, Germany)See Presenter abstractOpen the presentationWatch the Webcast
Hot Line: Heart failure: devices and interventions
© 2017 European Society of Cardiology. All rights reserved